Medidata Study Experience

  1. The Future Of Data Linkage In Clinical Trial Evidence Generation 12/20/2022

    Explore key questions about the future of AI and data linkage in clinical trial evidence generation.

  2. The Regulatory Grade External Control Arm To Power Your Clinical Trials 12/9/2022

    Examine the growing role of external control arms in clinical trials, including the distinctions between control groups that use real-world data and those that use historical clinical trial data.

  3. Imunon Phase IB Ovarian Cancer Study Shows Strong Progression-Free Survival Treatment Effect Using A Synthetic Control Arm 12/8/2022

    Explore how Imunon used a control arm among stage III/IV ovarian cancer patients in their clinical trial.

  4. Drive Possibility Forward 12/8/2022

    Medidata AI provides unparalleled clinical data, advanced analytics, and industry expertise to help reimagine what is possible through uncovering breakthrough insights, making confident decisions, and pursuing continuous innovation.

  5. Medidata AI Labs History 12/8/2022

    Medidata Al Labs focuses on working closely with clients to answer important questions as they work to bring therapies to
    patients faster.

  6. A Mid-Sized Sponsor Increased Site Count By 50% In A Rare Disease Clinical Trial 12/8/2022

    In this case study, explore how a mid-sized sponsor chose high-performing sites based on reliable data to set their trial up for success.

  7. Clinical Trials Are Better, Faster, Cheaper With Big Data 12/8/2022

    The path from study design to approval is long, winding, and expensive. Explore how researchers are using artificial intelligence and advanced analytics to speed up the process, reduce costs, and get effective treatments swiftly to those who need them while tapping into data on patients from past trials.

  8. Medicenna Gains Precedent-Setting FDA Approval 12/8/2022

    Learn how Medicenna was able to leverage Synthetic Control Arm (SCA) to bolster Phase 2 findings and gain FDA approval to design a hybrid external control arm for their Phase 3 registrational trial.

  9. Synthetic Control Arm In Clinical Trials 12/8/2022

    Get an overview of the SCA, an external control generated with the goal of improving the interpretation of uncontrolled trials, which can enable better product development decisions.

  10. Glioblastoma Multiforme 11/15/2022

    Medidata AI’s Synthetic Control Arm® (SCA®) leverages historical clinical trial data (HCTD) to provide a more relevant clinical insight for the purpose of developing new therapies.